共同度过
2021-11-24
起飞
Singapore Based iX Biopharma Hands Seelos Exclusive Rights For Wafermine For Pain Management
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":874826126,"tweetId":"874826126","gmtCreate":1637760166215,"gmtModify":1637760166215,"author":{"id":3500094346399605,"idStr":"3500094346399605","authorId":3500094346399605,"authorIdStr":"3500094346399605","name":"共同度过","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":22,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>起飞</p></body></html>","htmlText":"<html><head></head><body><p>起飞</p></body></html>","text":"起飞","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/874826126","repostId":1115573252,"repostType":2,"repost":{"id":"1115573252","pubTimestamp":1637756463,"share":"https://www.laohu8.com/m/news/1115573252?lang=&edition=full","pubTime":"2021-11-24 20:21","market":"us","language":"en","title":"Singapore Based iX Biopharma Hands Seelos Exclusive Rights For Wafermine For Pain Management","url":"https://stock-news.laohu8.com/highlight/detail?id=1115573252","media":"Benzinga","summary":"iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine,","content":"<p><b>iX Biopharma</b> has inked an exclusive agreement to license its lead drug under development, Wafermine, to <b>Seelos Therapeutics Inc</b>.</p>\n<ul>\n <li>Seelos will have exclusive worldwide rights for Wafermine, - for which iX Biopharma will retain the rights.</li>\n <li>Seelos will also have worldwide rights to products incorporating R- and S- enantiomers of ketamine being developed using iX Biopharma's WaferiX technology.</li>\n <li>As part of the deal, iX Biopharma will receive a $9 million upfront payment in cash and shares from Seelos. It is also eligible for up to $239 million in development and sales milestone payments.</li>\n <li>Moreover, iX Biopharma will receive \"double-digit\" percentage royalties on future net sales of any products which incorporate the R- and S- enantiomers of ketamine using its WaferiX technology.</li>\n <li>\"The licensing of the WaferiX drug delivery platform for sublingual (disintegrate under the tongue rapidly) ketamine broadens Seelos' ketamine franchise with formulations that we believe will be suitable for both acute and chronic dosing,\" said Raj Mehra, Chairman and CEO of Seelos.</li>\n <li>The Licensed Products will contain ketamine, which provides a non-opioid approach for treating pain by targeting the NMDA receptor.</li>\n <li><b>Price Action:</b> SEEL shares closed at $1.95 on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Based iX Biopharma Hands Seelos Exclusive Rights For Wafermine For Pain Management</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Based iX Biopharma Hands Seelos Exclusive Rights For Wafermine For Pain Management\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 20:21 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/11/24270268/singapore-based-ix-biopharma-hands-seelos-exclusive-rights-for-wafermine-for-pain-management><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics Inc.\n\nSeelos will have exclusive worldwide rights for Wafermine, - for which...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270268/singapore-based-ix-biopharma-hands-seelos-exclusive-rights-for-wafermine-for-pain-management\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SEEL":"Seelos Therapeutics, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24270268/singapore-based-ix-biopharma-hands-seelos-exclusive-rights-for-wafermine-for-pain-management","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115573252","content_text":"iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics Inc.\n\nSeelos will have exclusive worldwide rights for Wafermine, - for which iX Biopharma will retain the rights.\nSeelos will also have worldwide rights to products incorporating R- and S- enantiomers of ketamine being developed using iX Biopharma's WaferiX technology.\nAs part of the deal, iX Biopharma will receive a $9 million upfront payment in cash and shares from Seelos. It is also eligible for up to $239 million in development and sales milestone payments.\nMoreover, iX Biopharma will receive \"double-digit\" percentage royalties on future net sales of any products which incorporate the R- and S- enantiomers of ketamine using its WaferiX technology.\n\"The licensing of the WaferiX drug delivery platform for sublingual (disintegrate under the tongue rapidly) ketamine broadens Seelos' ketamine franchise with formulations that we believe will be suitable for both acute and chronic dosing,\" said Raj Mehra, Chairman and CEO of Seelos.\nThe Licensed Products will contain ketamine, which provides a non-opioid approach for treating pain by targeting the NMDA receptor.\nPrice Action: SEEL shares closed at $1.95 on Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1247,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/874826126"}
精彩评论